Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species
- Marija Iljina†1,
- Liu Hong1, 2,
- Mathew H. Horrocks1, 3,
- Marthe H. Ludtmann4,
- Minee L. Choi4,
- Craig D. Hughes5,
- Francesco S. Ruggeri1,
- Tim Guilliams1, 6,
- Alexander K. Buell1, 8,
- Ji-Eun Lee1,
- Sonia Gandhi4,
- Steven F. Lee1,
- Clare E. Bryant5,
- Michele Vendruscolo1,
- Tuomas P. J. Knowles1,
- Christopher M. Dobson1Email author,
- Erwin De Genst†1, 7Email author and
- David Klenerman1Email author
© Klenerman et al. 2017
Received: 11 April 2017
Accepted: 6 June 2017
Published: 3 July 2017
The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson’s disease. One widely explored therapeutic strategy for these conditions is the use of antibodies to target aggregated ɑS, although a detailed molecular-level mechanism of the action of such species remains elusive. Here, we characterize ɑS aggregation in vitro in the presence of two ɑS-specific single-domain antibodies (nanobodies), NbSyn2 and NbSyn87, which bind to the highly accessible C-terminal region of ɑS.
We show that both nanobodies inhibit the formation of ɑS fibrils. Furthermore, using single-molecule fluorescence techniques, we demonstrate that nanobody binding promotes a rapid conformational conversion from more stable oligomers to less stable oligomers of ɑS, leading to a dramatic reduction in oligomer-induced cellular toxicity.
The results indicate a novel mechanism by which diseases associated with protein aggregation can be inhibited, and suggest that NbSyn2 and NbSyn87 could have significant therapeutic potential.
KeywordsProtein aggregation Amyloid toxicity Neurodegeneration Aggregation inhibitors Antibody Single-molecule fluorescence
The aberrant aggregation of the protein ɑ-synuclein (ɑS) has been linked to the onset and progression of Parkinson’s disease (PD), dementia with Lewy bodies , PD dementia, multiple system atrophy, and related synucleopathies [2–4]. The histopathological characteristics of PD and its associated disorders include the presence of neuronal inclusions, for example, Lewy bodies and Lewy neurites, which are primarily composed of fibrillar ɑS [1, 5]. The deposition of ɑS in the nervous system follows a characteristic pattern , and the ability of aggregated species to propagate across the brain by a mechanism that is defined as prion-like is increasingly recognized . In aqueous solution, monomeric ɑS self-assembles into amyloid fibrils resembling those that are deposited in the brain, and the aggregation process proceeds through the formation of intermediate species, including soluble oligomers, prior to fibril formation [8, 9]. Moreover, these oligomeric species, rather than mature amyloid fibrils, have increasingly been identified as the most highly neurotoxic forms of ɑS [10–16].
As a consequence of the central role of ɑS aggregation in PD and the neurotoxicity of its assemblies, immunotherapy against ɑS is being widely pursued as a potential disease-modifying strategy [17, 18]. Although passive immunization using antibodies targeting ɑS has shown promise in numerous in vitro and in vivo model systems, as well as in several clinical trials [19, 20], there is no effective treatment for PD and other synucleinopathies. In order to make significant advances in this objective, it is crucial to develop a detailed understanding of the molecular mechanism of action of ɑS-specific antibodies during the aggregation process of the protein.
Over the years, full-length antibodies and antibody fragments, such as scFvs, have been generated against different regions and different species of ɑS for either biophysical studies, target validation, or therapy (reviewed in De Genst et al.  and Bergstrom et al. ), and have been used in multiple reported studies [22–27].
Full-length ɑS consists of 140 amino acid residues divided into three distinct regions, namely a positively charged lipid-binding N-terminal segment comprising residues 1–60, a central hydrophobic segment consisting of residues 61–95, and a negatively-charged C-terminal region comprising residues 96–140 . This latter region does not include the residues observed to be in the amyloid fibril core , although previous in vitro studies have shown that its deletion promotes ɑS aggregation , indicating its involvement in the aggregation process. Notably, antibodies directed to the C-terminal region of ɑS, or specific for oligomeric forms of ɑS, were reported both to suppress strongly its aggregation and to reduce cellular toxicity [24, 27].
We have previously described two single-domain fragments of camelid heavy-chain antibodies , termed ‘nanobodies’ , denoted NbSyn2  and NbSyn87 , which bind to distinctive epitopes within the C-terminal region of monomeric ɑS (residues 137–140 and 118–131, respectively). These nanobodies, which were raised against and bind to monomeric ɑS, also recognize fibrillar forms of ɑS in which the C-terminal region is exposed , allowing the use of these nanobodies as biophysical probes to study the properties of ɑS fibrils . Moreover, one of these nanobodies, NbSyn87, when expressed as a genetic fusion protein with a PEST proteasomal degradation tag, was found to reduce toxicity in cell-lines overexpressing ɑS as a result of the specific degradation of monomeric ɑS, thereby significantly reducing proteostatic stress .
In order to understand such phenomena in molecular detail, it is important to characterize the impact of nanobody binding on the overall ɑS aggregation process in vitro, and in particular its effect on the formation of the highly toxic oligomers that are linked to cellular damage. It is known from previous studies that the C-terminal region of ɑS is exposed in at least some of its aggregated intermediate forms, such as oligomers , as well as monomers and fibrils, and that targeting of this region by antibodies has been recognized to have protective effects . Therefore, it is plausible that the nanobodies and other C-terminal-binding antibodies can affect the formation and properties of these oligomers.
Since the pre-fibrillar oligomers are generally transient and heterogeneous, and are typically present at very low concentrations relative to ɑS monomers, they are difficult to study by conventional bulk techniques. We have previously utilized single-molecule Förster resonance energy transfer (sm-FRET) measurements in order to characterize the oligomerization of ɑS in considerable detail [13, 37]. Using this technique, we identified two distinct types of ɑS oligomers that were populated sequentially prior to the formation of ɑS fibrils . The two oligomer types had distinct FRET efficiency distributions and were therefore termed “low-FRET” and “high-FRET” oligomers . The differences in their photophysical properties, as well as their different kinetics of formation, stabilities towards dissociation and enzymatic proteolysis, and toxicity to cells indicated that these two oligomer forms were structurally distinct intermediates generated in the process of the formation of ɑS fibrils [13, 38]. In particular, the initial assembly of low-FRET oligomers was followed by slow conformational conversion into high-FRET oligomers prior to fibril formation. The accumulation of high-FRET oligomers was associated with the highest level of cytotoxicity, pointing to this specific oligomer type as the most damaging species formed during ɑS aggregation.
In this study, we set out to characterize in detail the effects of NbSyn2 and NbSyn87 on the aggregation of ɑS in vitro. First, we investigated fibril formation using a combination of biophysical experiments to monitor the kinetics of this process, and compared the properties of the various resulting fibrillar aggregates. Second, we employed sm-FRET techniques to explore how the presence of NbSyn87 and NbSyn2 affects the formation of the low-FRET and high-FRET oligomers. We identified the ability of the nanobodies to inhibit the formation of ɑS fibrils and to destabilize toxic high-FRET oligomers of ɑS, and explored how the latter process affects oligomer-induced cytotoxicity.
NbSyn2 and NbSyn87 inhibit the formation, maturation, and elongation of ɑS fibrils
We first investigated the effects of the ɑS-specific nanobodies, NbSyn87 and NbSyn2, on ɑS fibril formation. To determine whether or not the binding of nanobodies to the C-terminal region affects the aggregation propensity of ɑS, we initially performed bulk solution aggregation assays to monitor fibril formation by full-length wild-type (wt) ɑS using thioflavin T (ThT) fluorescence measurements to monitor the quantity of aggregated ɑS. In these experiments, ɑS at a concentration of 70 μM was aggregated in the absence or presence of 140 μM NbSyn2, NbSyn87, or a control nanobody, cAbHuL5g (NbHul5g) ; the latter is a lysozyme-specific nanobody  and is therefore not expected to bind to ɑS.
The aggregation kinetics of ɑS in the absence of nanobodies are in good agreement with our previously reported bulk kinetic measurements of ɑS under similar incubation conditions [13, 37]. In contrast, moderate inhibition of fibril formation was observed in the presence of NbSyn2, whereas solutions incubated in the presence of NbSyn87 gave rise to much lower ThT fluorescence signals over the entire duration of the experiment, indicating a stronger inhibition of ɑS fibril formation in the presence of this nanobody [13, 37]. In addition, we confirmed the inhibition of the formation of ThT-active aggregates in the presence of NbSyn2 and NbSyn87 by total internal reflection fluorescence microscopy imaging of the solutions extracted during the process of the aggregation reaction (Additional file 1: Figure S1).
Subsequently, we characterized the end products of aggregation using atomic force microscopy (AFM). In agreement with the findings from the ThT fluorescence assays, the images obtained in this way showed the presence of large numbers of amyloid fibrils in the solutions of ɑS that had been incubated in the absence of nanobodies or in the presence of NbHul5g or NbSyn2 (Fig. 1b). In the samples of ɑS incubated with NbSyn87, only small and apparently spherical aggregates along with monomeric species were observed, and no large fibrils could be detected (Fig. 1b). Comparison of average fibril heights from AFM maps revealed that fibrils formed in the presence of NbSyn2 were thinner than fibrils formed in the absence of nanobodies or in the presence of NbHul5g (Fig. 1c and Additional file 1: Figure S1), indicating that nanobodies impaired the maturation of ɑS fibrils. The differences in the fibril-forming capability of ɑS identified in the presence of the two ɑS-specific nanobodies might be due to the differences in the epitopes they bind. NbSyn87 binds with higher affinity and closer to the NAC region than does NbSyn2, and thereby might slow fibril formation due to steric hindrance and promote the formation of smaller fibrils (Fig. 1b).
We also performed quartz crystal microbalance experiments [40, 41] in order to measure the effects of NbSyn2 and NbSyn87 on the elongation rates of pre-formed ɑS fibrils upon their incubation with either monomeric ɑS, or with a stoichiometric ratio of monomeric ɑS and NbSyn87, NbSyn2, or NbHul5g (Additional file 2). It was found that the elongation rate of ɑS fibrils markedly decreased in the presence of both ɑS-specific nanobodies, corresponding to 30–40% of the rate in their absence, as described in further detail in Additional file 2: Tables S3 and S4, and discussed in Additional file 2: Supplementary Results.
NbSyn2 and NbSyn87 impede the generation of high-FRET oligomeric species of ɑS prior to fibril formation
In sm-FRET experiments, equimolar mixtures of AF488-labeled ɑS (AF488-ɑS) and AF594-labeled ɑS (AF594-ɑS) were used at a total protein concentration of 70 μM, either in the presence or absence of 140 μM of unlabeled nanobodies. The solutions were incubated with agitation under the same conditions as in the bulk ThT assays, and aliquots were withdrawn at regular time intervals during the incubation, diluted 105-fold to generate appropriate conditions for single-molecule detection, and immediately analyzed by sm-FRET. We analyzed the solutions both following their dilution into aqueous buffer of the same composition as that used for the incubations (PBS, see in Methods), and following dilution into deionized water; we have recently shown that dilution into low ionic strength solutions enables an improved separation of the low- and high-FRET oligomers . We measured the average brightness of AF488-ɑS and AF594-ɑS in the presence of the unlabeled nanobodies to verify that the nanobodies did not affect the fluorescence properties of the dyes in the sm-FRET experiments (Additional file 2: Supplementary Information). In addition, we carried out control experiments using samples where both ɑS and nanobodies were labeled with AF to confirm that the nanobodies were fully dissociated from ɑS during the detection step under both solution conditions; the results were consistent with previously reported Kd values , as detailed in Additional file 2: Supplementary Methods and Tables S1 and S2.
The resulting kinetic profiles of ɑS monomer depletion and oligomer formation are shown in Fig. 1d–g. The most rapid decrease in the monomer concentration, deduced from the monomer burst-rates , occurred in the samples containing 70 μM ɑS alone or in the presence of the control NbHul5g (Fig. 1d, e). However, samples containing NbSyn87 and NbSyn2 showed significantly slower monomer depletion. Based on the monomer depletion data derived from sm-FRET, after 30 h of aggregation, approximately 70% of the sample was aggregated in the ɑS-only reaction, 90% in the ɑS plus control nanobody, and approximately 40% in the samples containing both ɑS and NbSyn87 or NbSyn2. The oligomers were formed in all samples, and comprised less than 2% of the samples of ɑS (Fig. 1d–g).
Transmission electron microscopy (TEM) images of the samples at incubation times longer than 100 h confirmed the presence of abundant quantities of amyloid fibrils in the solutions containing ɑS alone or in the presence of NbHul5g and of NbSyn2, while only oligomers and short protofibrils were detected in the presence of NbSyn87 (Additional file 3: Figure S2b). These results confirm that the nanobodies inhibit ɑS fibril formation, and are therefore in good agreement with the bulk ThT fluorescence data and AFM results obtained for wt unlabeled ɑS as detailed above (Fig. 1b).
To elucidate the effects of the nanobodies on the formation of the low-FRET and high-FRET oligomers, individual FRET efficiency histograms of the samples recorded following dilution into water were analyzed. These showed clear differences between the control samples and the samples containing ɑS-specific NbSyn2 and NbSyn87 (Fig. 2). As in our previous work [13, 37], we separated the FRET efficiency histograms into two groups, corresponding to the histograms derived from “small” oligomers containing 2–5 apparent monomer units (denoted as “small-mers”) and oligomers containing 6–150 apparent monomer units (“large-mers”), based on the number of peaks that were resolvable in the FRET efficiency histograms, as previously reported . This procedure allows us to identify the time-dependent changes readily, which are most clearly evident in the histograms for the large oligomers formed during aggregation (Fig. 2).
For the samples of ɑS alone, and ɑS in the presence of control NbHul5g, two peaks could be observed in the FRET efficiency histograms of the large-mers (Fig. 2), corresponding to the two previously identified oligomer populations [13, 37, 38]. Low-FRET oligomers are characterized by a population centered at an average FRET efficiency value (E) of 0.5, and high-FRET oligomers are indicated by the peak centered at E value of approximately 0.8 (Fig. 2). The high-FRET population was clearly distinguishable after 24 h of aggregation and was dominant by 30 h of incubation both in the absence of nanobodies and in the presence of the control nanobody (Fig. 2), in good agreement with our previously reported kinetics of high-FRET oligomer formation [13, 37]. The mild acceleration of the formation of high-FRET species in the presence of the control nanobody NbHul5g compared to the ɑS-only sample might be due to the crowding effect or transient interactions of NbHul5g with ɑS. Instead of exhibiting two populations at times longer than 24 h, however, the FRET histograms of oligomers formed in the presence of ɑS-specific nanobodies showed a single broad peak. The appearance of these histograms resembles those that had been obtained previously for ɑS solutions at low concentrations, in which high-FRET oligomers were not formed at high levels, yet were not fully absent . Therefore, the appearance of the FRET efficiency histograms suggests that, in the presence of ɑS-specific nanobodies, the formation of high-FRET oligomers is impeded.
To characterize quantitatively the observed differences in ɑS oligomer populations either in the absence or presence of the nanobodies, we carried out a detailed kinetic analysis by fitting the experimental aggregation profiles to a nucleation-conversion-polymerization model similar to that reported previously . A description of the analysis and the rate constants obtained for the individual microscopic steps of the aggregation process are available in Additional file 2: Supplementary Information and Additional file 4: Figure S3. We achieved the closest agreement with experimental data by assuming that both of the ɑS-specific nanobodies accelerate the reverse microscopic reaction steps, i.e., the conformational conversion from high-FRET oligomers to low-FRET oligomers and subsequently to monomers. This increase in rate results in the net inhibition of the overall forward aggregation process in the presence of NbSyn2 and NbSyn87, and successfully explains the experimentally observed reduced proportion of high-FRET oligomers and the altered kinetics of monomer depletion and fibril formation. Furthermore, this analysis predicted the distinct accumulation of low-FRET oligomers over longer aggregation times (Additional file 4: Figure S3). In the following section we discuss direct evidence for these phenomena.
NbSyn2 and NbSyn87 enhance the conversion of high-FRET into low-FRET oligomeric species
Having characterized the kinetics of ɑS aggregation in the presence of NbSyn2 and NbSyn87, we set out to obtain direct evidence to support the conclusion that the nanobodies could promote the conformational conversion step from high-FRET to low-FRET species. To this end, we tested whether or not the addition of the nanobodies promoted the dissociation of pre-formed high-FRET oligomeric species. For these experiments, solutions from the aggregation reactions of 70 μM labeled ɑS in the absence of nanobodies were collected after 29 h of incubation and analyzed by sm-FRET to monitor the presence of high-FRET oligomers.
Subsequently, two molar equivalents of unlabeled NbSyn2, NbSyn87 or NbHul5g were added to these samples prior to sm-FRET measurement. The representative contour plots of FRET efficiencies and apparent oligomer sizes, as well as the FRET efficiency histograms of each sample (Fig. 3) show highly reproducible results as nearly identical outcomes were observed in at least five independent experiments where fresh nanobodies were added to pre-formed high-FRET oligomers. The addition of NbSyn2 or NbSyn87 resulted in a reproducible decrease of the mean FRET efficiency values (Fig. 3b). These changes in FRET efficiencies cannot be explained by optical effects, e.g., quenching of fluorescence due to the binding of the nanobodies to the oligomeric species, because the samples were diluted by a factor of 105, bringing the concentration of the NbSyn87 and NbSyn2 significantly below the Kd values of the interaction of the nanobodies with monomeric ɑS, as in all previous sm-FRET measurements . In addition, the koff values for NbSyn87 and NbSyn2 are the order of 0.01 and 0.1 s–1, respectively (Additional file 2: Supplementary Methods), indicating that the complexes would dissociate upon dilution, an assumption that was confirmed by the experimentally observed absence of coincidence between the labeled nanobody and ɑS under our detection conditions.
The conformational conversion from high- to low-FRET oligomers described here was observed upon the addition of two molar equivalents of nanobodies. We also carried out titrations to determine the lowest stoichiometric ratio of the nanobodies to ɑS at which this behavior is observable. The reduction in FRET efficiencies in this experiment could be clearly observed down to 0.5 molar equivalents of the nanobodies, while at concentrations below 0.25 molar equivalents this process was too slow to be observed even upon incubation for 10 h (Additional file 5: Figure S4).
The reduced population of high-FRET oligomers in the presence of NbSyn87 and NbSyn2 leads to significantly reduced cellular damage
The observation that NbSyn2 and NbSyn87 impair the formation of high-FRET oligomer types during the aggregation process and induce a more rapid conformational conversion of pre-formed high-FRET oligomers into low-FRET species, prompted us to test if these effects could result in an overall decrease in the average stability and cytotoxicity of the oligomers generated at the early stages of the aggregation process of ɑS.
We then investigated if the inhibitory effect of the nanobodies at early stages of the aggregation reaction could result in a change in oligomer-induced cellular damage. High-FRET oligomers have been found in previous studies to induce significantly higher levels of cellular toxicity in rat mid-brain neuronal cultures than the low-FRET species [13, 37, 42]. Aliquots were extracted from samples of ɑS undergoing aggregation in the absence or presence of nanobodies after incubation for 29 h, and the production of reactive oxygen species (ROS) was measured following the application of these solutions to primary co-cultures of neurons and astrocytes (Additional file 2: Supplementary Information). The results show that the presence of NbSyn87 or NbSyn2 led to a significantly reduced rate of ROS production in comparison to the samples generated in their absence or in the presence of the control nanobody NbHul5g (Fig. 4c). This observed reduction in the oligomer-induced ROS indicates a reduced proportion of toxic high-FRET oligomers and supports the sm-FRET and proteinase K digestion results described above. We also investigated the ability of ɑS oligomer populations prepared in the presence or absence of nanobodies to induce cell death (see Additional file 2: Supplementary Information for details).
We found that the incubation of cells with ɑS aggregated in the presence of either NbSyn87 or NbSyn2 led to a significant reduction in cell death in comparison to the incubation of ɑS alone (Fig. 4d), indicating in the former the presence of a lower proportion of high-FRET compared to low-FRET oligomers. Apart from the significantly reduced cytotoxicity upon application of nanobody-bound oligomers in comparison to the oligomers of ɑS alone in ROS and cell death assays, it was found that the samples containing NbSyn2 reduced the cytotoxicity more effectively in comparison to NbSyn87 (Fig. 4c, d). While the overall reduction of cytotoxicity in comparison to the ɑS-only samples is entirely consistent with the measured ability of NbSyn87 and NbSyn2 to convert toxic high-FRET oligomers to low-FRET oligomers in aqueous solution, the difference between the two ɑS-specific nanobodies suggests the influence of other factors in the cell milieu in addition to the structure of ɑS oligomers. The lower protective effect of NbSyn87 compared to NbSyn2 in these experiments might be due to the high positive charge of NbSyn87 (pI > 9.0) and increased interaction with the cell membranes, as well as due to its ability to abolish ɑS fibril formation leading to the increased oligomer load. More detailed comparison of the reduction of toxicity by NbSyn2 and NbSyn87 in the cellular environment remains to be made in future studies.
Finally, we tested whether or not the oligomers formed in the presence of the ɑS-specific nanobodies reduced the pro-inflammatory activation of microglial cells by quantifying the concentration of the released pro-inflammatory cytokine, the tumor necrosis factor alpha (TNF-ɑ) protein , upon their incubation with ɑS solutions after aggregation for 29 h. The experimental procedure is described in Additional file 2: Supplementary Information, and the results show that the application of ɑS solutions aggregated with NbSyn2 and NbSyn87 resulted in a significantly reduced activation of microglia in comparison to ɑS alone and/or NbHul5g-containing samples (Fig. 4e).
Taken together, the comparative assays in Fig. 4 indicate a lower average stability of the ɑS oligomer populations generated in the presence of the ɑS-specific nanobodies and a reduced propensity to cause cellular damage. These findings are completely consistent with the conclusion that the population of the more toxic high-FRET oligomer type is reduced during the aggregation process of ɑS in the presence of NbSyn87 and NbSyn2.
In this study, we have characterized the key molecular steps that are altered by the ɑS-specific nanobodies, NbSyn2 and NbSyn87, during the aggregation reaction of ɑS. We have observed a clear effect of NbSyn2 and NbSyn87 on the formation of ɑS fibrils and their resulting morphology. In addition, using single-molecule fluorescence measurements we have identified a selective action of the nanobodies at the earliest stages of the aggregation reaction associated with the formation of toxic oligomeric species. In particular, both nanobodies were found to slow down the conformational conversion from less stable low-FRET oligomers to more stable high-FRET oligomers. Moreover, we observed that both NbSyn2 and NbSyn87 are able rapidly to convert pre-formed high-FRET oligomers to low-FRET species, indicating that the high-FRET oligomers are destabilized upon the binding of these nanobodies. These effects are associated with a significant reduction of cytotoxicity induced by the oligomers.
The ability of the nanobodies to promote the direct conformational conversion from more toxic to less toxic oligomeric species demonstrated in this study indicates the existence of an influential and unexplored mode of action of nanobodies or antibodies. Previously established modes of action of antibodies and nanobodies in vitro have included those that alter the equilibrium between fibrils, oligomers, and monomers , which can take a finite length of time to make sufficient changes in oligomer concentrations, and those that target oligomers to decrease their binding to cell membranes [11, 45]. The rapid conformational conversion by nanobodies of toxic oligomers to less toxic oligomers identified in our experiments has a direct effect on their ability to cause cellular damage. The results suggest, therefore, that the ability of nanobodies to promote conformational conversion of oligomers could have important potential for the development of therapeutic strategies. Since our study has been performed in vitro and at high concentrations of ɑS, it will be of interest to elucidate the role of this mechanism under a more complex biological environment in vivo in future investigations.
The ability of the nanobodies to destabilize high-FRET oligomers observed here may be due to a combination of their significantly smaller size than conventional antibodies  and their binding to the accessible C-terminal region of the protein [33, 34]. Antibodies binding to the C-terminal region of ɑS have previously been shown to decrease the production of highly aggregation-prone truncated forms of ɑS lacking the C-terminal region . Thus, steric effects could be an important feature in enabling the smaller nanobodies to interact more effectively with oligomers than larger antibodies and further comparison of the action of nanobodies and conventional antibodies is warranted. Optimization of this destabilization effect in future work by probing the nanobody binding site in further detail may be possible through approaches that can distinguish between different oligomer structures, and hence measure the extent of destabilization.
This study has involved the detailed biophysical characterization of the role of ɑS-specific nanobodies on the aggregation of ɑS in vitro, including the use of single-molecule fluorescence techniques. It shows that nanobodies targeting the C-terminal region inhibit the aggregation of ɑS not only by inhibiting its aggregation and elongation processes, but also by inhibiting the conformational conversion of oligomers formed prior to fibril formation. The latter effect leads to the decrease in oligomer stability and significantly reduces the cellular damage resulting from the effects of oligomeric species. Our work reveals an important mode of action of nanobodies, namely their ability rapidly to convert already formed toxic oligomers to less toxic ones. Such a mode of action has the potential to form the basis for a therapeutic strategy to combat PD and related protein misfolding conditions.
Expression and purification of nanobodies and ɑS
NbSyn87, NbSyn2, and NbHul5g were expressed in the periplasm of E. coli cells and purified using immobilized metal affinity chromatography and size-exclusion chromatography as previously described . The amino acid sequences of NbSyn87 and NbSyn2 were as previously reported . The sequence and structure of NbHul5g and the details of the construction of its more stable variant NbHul5g has been previously reported . Expression and purification of wt and the alanine to cysteine mutant at position 90 (A90C) ɑS were carried out according to published protocols .
ThT aggregation assays
Solutions of 600 μL of wt ɑS at a concentration of 70 μM either with or without 2 molar equivalents of NbSyn87, NbSyn2, or NbHul5g in PBS buffer (10 mM phosphate, pH 7.5, 100 mM NaCl, 2 mM EDTA, and 0.1% NaN3) were incubated for a period of 107 h at 37 °C with constant agitation at 200 rpm (New Brunswick Scientific Innova 43). Aliquots of 5 μL were removed at various time points and added to a 95 μL ThT solution (20 μM) in PBS buffer. ThT fluorescence was measured using a Cary Eclipse fluorimeter (Varian) with excitation and emission wavelengths of 440 and 480 nm, respectively. The mean maximum intensities from triplicate measurements were reported.
The end-point samples from the aggregation procedures used for the ThT assay were visualized using AFM imaging. Cleaved mica surfaces were incubated for 1 min with 10 μL of 0.5% (v/v) (3-aminopropyl)triethoxysilane (Sigma-Aldrich) in deionized water (Milli-Q). Then, the surfaces were rinsed three times with 1 mL of deionized water (Milli-Q) and dried with a gentle stream of nitrogen. For each sample, 10 μL of the solution was deposited on the positively functionalized surface. The droplet was incubated for 10 min, then rinsed with 1 mL of deionized water (Milli-Q) and dried with a gentle stream of nitrogen; all procedures were carried out at room temperature. AFM maps were acquired using JPK Nanowizard 2 system operating in tapping mode and equipped with a silicon tip (Micromasch, 2 Nm–1) with a nominal radius of 10 nm. Image flattening was performed by SPIP (Image Metrology) software. Analysis of mean fibril heights was carried out as previously reported  and described in detail in Additional file 2: Supplementary Information.
The A90C mutant variant of ɑS was labeled with either maleimide-modified AF488 or AF594 dyes (Life Technologies) via the cysteine thiol moiety as previously reported [13, 49]. The labeled protein was purified from the excess of free dye using a P10 desalting column with Sephadex G25 matrix (GE Healthcare) and concentrated using Amicon Ultra Centricons (Millipore), divided into aliquots, flash frozen and stored at −80 °C. Each aliquot was thawed immediately and used only once.
Estimation of the concentration of free ɑS
where [as] bound is the concentration of bound ɑS, [as] and [Nb] are the starting concentrations of ɑS and nanobody, and K d is the corresponding dissociation constant .
The experiments were carried out according to previously published procedures [37, 38], utilizing a custom-built single-molecule setup as already described  and microfluidic devices fabricated as previously reported . The single-molecule instrumentation has been previously described in detail . For the aggregation reactions, equimolar concentrations of AF488- and AF594-labeled A90C ɑS (AF488-ɑS and AF594-ɑS) in PBS were combined to a final volume of 300 μL, bringing the total ɑS concentration to 70 μM, either in the presence or absence of 140 μM of unlabeled NbSyn87, NbSyn2, or NbHul5g. At least three separate samples were prepared and analyzed at each protein combination. The solutions were incubated in the dark for up to 50 h under the same incubation conditions as the samples for ThT assays (37 °C, with agitation). Aliquots were withdrawn at regular time intervals and diluted 2.5 × 105 fold by serial dilution in either PBS buffer or deionized water (Milli-Q) to give a concentration suitable for analysis in the single molecule regime. Immediately upon dilution, the solution was passed at a constant rate of 2 cm s–1 (syringe pump PHD2000, Harvard Apparatus) through a channel of a microfluidic device mounted on the single-molecule confocal microscope (Nikon Eclipse Ti-U). The 488 nm laser beam was focused into the center of the channel (10 μm along vertical direction). The experimental data consisted of synchronous time-binned fluorescence output from the donor (AF488) and the acceptor (AF594) channels, acquired for 400 s per aliquot (80 frames, 100,000 bins frame–1, 50 μs bin-width). The absence of oligomer dissociation during sm-FRET detection was previously confirmed , and the estimated oligomer concentrations were previously found to agree with the oligomer concentrations at bulk conditions .
Sm-FRET data analysis
where I D is the donor intensity in the presence of an acceptor, I A is the acceptor intensity, \( \gamma \) is the gamma factor, which corrects for the differences in detection efficiencies of the two fluorescent probes and their quantum yields (\( \gamma \) = 0.99), and I monomer is the mean monomer brightness, averaged over all of the non-coincident bursts in the donor channel. FRET efficiency and apparent size distributions were represented as histograms with bin-widths of 0.05 and 1, respectively. The presence of undetectable singly-colored or fluorescently quenched oligomers was assumed to have no significant effect on the data, based on our previous works [13, 38]. Large species, either those apparently greater than 150 monomers in size or occupying consecutive time-bins, were assumed to be due to fibrillar species and were excluded from the analysis, as reported in our previous study . Subsequently, both the monomer and the oligomer bursts were converted into corresponding bulk ɑS concentrations by taking into account the dilution factor, as previously reported .
We are grateful to Ewa Klimont and Swapan Preet for the expression and purification of A90C ɑS, and thank Dr. Yu Ye for the reagents used in the proteasome degradation assays.
MI was funded by a Dr Tayyeb Hussain Scholarship and the ERC (669237). LH was funded by a China Scholarship Council and NSFC 11204150. TG was a recipient of a studentship from Parkinson’s UK (H-0903). EDG was supported by the Medical Research Council (MRC G1002272). DK was funded by the ERC (669237) and the Royal Society, CMD, TPJK and MV by the Wellcome Trust.
Availability of data and materials
All experimental methods and results generated during this study are included in the article and in Additional file 2: Supplementary Information (SI.pdf), available online. The individual data values for the datasets in Figs. 1 and 4 are included as an Additional file 7: Supporting Data Values.xls.
MI designed and performed the single-molecule fluorescence experiments and data analysis. EDG performed the nanobody preparation, bulk thioflavin T assays, and aided with single-molecule experiments. LH performed the kinetic analysis. MHH aided with the single-molecule experiments and the design of the project. MHL, MLC, and CDH performed the cell experiments. SG and CEB designed the cell experiments. FSR performed the AFM measurements and analysis. AKB performed the quartz crystal microbalance experiments. TG performed the nanobody preparation. JEL and SFL performed total internal reflection fluorescence microscopy imaging and data analysis. TPJK and MV supervised the study. CMD, EDG, and DK designed and supervised the study. MI, EDG, DK, and CMD wrote the paper, with contributions from all authors. All authors read and approved the final manuscript.
The authors declare no competing financial interests.
Consent for publication
Ethics approval and consent to participate
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879–84.PubMedPubMed CentralGoogle Scholar
- Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol. 1999;58:1263–8.View ArticlePubMedGoogle Scholar
- Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998;249:180–2.View ArticlePubMedGoogle Scholar
- Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology. 1998;51:887–9.View ArticlePubMedGoogle Scholar
- Spillantini M, Crowther R, Jakes R, Cairns N, Lantos P, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett. 1998;251:205–8.View ArticlePubMedGoogle Scholar
- Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42:33–50.View ArticlePubMedGoogle Scholar
- Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain. 2017;140(Pt 2):266–78.View ArticlePubMedGoogle Scholar
- Fink AL. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res. 2006;39:628–34.View ArticlePubMedGoogle Scholar
- Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TP, Linse S, Dobson CM. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc Natl Acad Sci U S A. 2014;111:7671–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Conway K, Lee S, Rochet J, Ding T, Williamson R, Lansbury P. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97:571–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013;73:155–69.View ArticlePubMedGoogle Scholar
- Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001;40:7812–9.View ArticlePubMedGoogle Scholar
- Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell. 2012;149:1048–59.View ArticlePubMedPubMed CentralGoogle Scholar
- Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain. 2015;138:1642–57.View ArticlePubMedPubMed CentralGoogle Scholar
- Näsström T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A, Ekberg M, Lannfelt L, Ingelsson M, Bergström J. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med. 2011;50:428–37.View ArticlePubMedGoogle Scholar
- Diógenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, Guerreiro P, Näsström T, Franquelim HG, Oliveira LM, Castanho MA, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012;32:11750–62.View ArticlePubMedGoogle Scholar
- Bellucci A, Navarria L, Zaltieri M, Missale C, Spano P. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res. 2012;1432:95–113.View ArticlePubMedGoogle Scholar
- George S, Brundin P. Immunotherapy in Parkinson's disease: micromanaging alpha-synuclein aggregation. J Parkinsons Dis. 2015;5:413–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Valera E, Spencer B, Masliah E. Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics. 2016;13:179–89.View ArticlePubMedGoogle Scholar
- Bergström AL, Kallunki P, Fog K. Development of passive immunotherapies for synucleinopathies. Mov Disord. 2016;31:203–13.View ArticlePubMedGoogle Scholar
- De Genst E, Messer A, Dobson CM. Antibodies and protein misfolding: from structural research tools to therapeutic strategies. Biochim Biophys Acta. 1844;2014:1907–19.Google Scholar
- Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y, Messer A, Sierks MR. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry. 2004;43:2871–8.View ArticlePubMedGoogle Scholar
- Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem. 2009;284:11048–58.View ArticlePubMedPubMed CentralGoogle Scholar
- Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol. 2007;368:1132–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther. 2004;10:1023–31.View ArticlePubMedGoogle Scholar
- Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol. 2008;377:136–47.View ArticlePubMedGoogle Scholar
- Näsström T, Gonçalves S, Sahlin C, Nordström E, Screpanti Sundquist V, Lannfelt L, Bergström J, Outeiro TF, Ingelsson M. Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One. 2011;6:e27230.View ArticlePubMedPubMed CentralGoogle Scholar
- Bisaglia M, Mammi S, Bubacco L. Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J. 2009;23:329–40.View ArticlePubMedGoogle Scholar
- Der-Sarkissian A, Jao C, Chen J, Langen R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J Biol Chem. 2003;278:37530–5.View ArticlePubMedGoogle Scholar
- Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, Trojanowski JQ, Lee VM. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry. 2003;42:8530–40.View ArticlePubMedGoogle Scholar
- Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8.View ArticlePubMedGoogle Scholar
- Muyldermans S. Single domain camel antibodies: current status. J Biotechnol. 2001;74:277–302.PubMedGoogle Scholar
- De Genst EJ, Guilliams T, Wellens J, O'Day EM, Waudby CA, Meehan S, Dumoulin M, Hsu ST, Cremades N, Verschueren KH, et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol. 2010;402:326–43.View ArticlePubMedGoogle Scholar
- Guilliams T, El-Turk F, Buell AK, O'Day EM, Aprile FA, Esbjörner EK, Vendruscolo M, Cremades N, Pardon E, Wyns L, et al. Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. J Mol Biol. 2013;425:2397–411.View ArticlePubMedGoogle Scholar
- Butler DC, Joshi SN, Genst E, Baghel AS, Dobson CM, Messer A. Bifunctional anti-non-amyloid component α-Synuclein nanobodies are protective in situ. PLoS One. 2016;11:e0165964.View ArticlePubMedPubMed CentralGoogle Scholar
- Mysling S, Betzer C, Jensen PH, Jorgensen TJ. Characterizing the dynamics of α-synuclein oligomers using hydrogen/deuterium exchange monitored by mass spectrometry. Biochemistry. 2013;52:9097–103.View ArticlePubMedGoogle Scholar
- Iljina M, Garcia GA, Horrocks MH, Tosatto L, Choi ML, Ganzinger KA, Abramov AY, Gandhi S, Wood NW, Cremades N, et al. Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proc Natl Acad Sci U S A. 2016;113(9):E1206–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Horrocks MH, Tosatto L, Dear AJ, Garcia GA, Iljina M, Cremades N, Dalla Serra M, Knowles TP, Dobson CM, Klenerman D. Fast flow microfluidics and single-molecule fluorescence for the rapid characterization of α-synuclein oligomers. Anal Chem. 2015;87:8818–26.View ArticlePubMedGoogle Scholar
- De Genst E, Chan PH, Pardon E, Hsu ST, Kumita JR, Christodoulou J, Menzer L, Chirgadze DY, Robinson CV, Muyldermans S, et al. A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation. J Phys Chem B. 2013;117:13245–58.View ArticlePubMedPubMed CentralGoogle Scholar
- Knowles TP, Shu W, Devlin GL, Meehan S, Auer S, Dobson CM, Welland ME. Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass. Proc Natl Acad Sci U S A. 2007;104:10016–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Buell AK, Dobson CM, Welland ME. Measuring the kinetics of amyloid fibril elongation using quartz crystal microbalances. Methods Mol Biol. 2012;849:101–19.View ArticlePubMedGoogle Scholar
- Deas E, Cremades N, Angelova PR, Ludtmann MH, Yao Z, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, et al. Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease. Antioxid Redox Signal. 2016;24:376–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Stefanova N, Schanda K, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. J Neurosci Res. 2003;73:334–40.View ArticlePubMedGoogle Scholar
- Pain C, Dumont J, Dumoulin M. Camelid single-domain antibody fragments: uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. Biochimie. 2015;111:82–106.View ArticlePubMedGoogle Scholar
- Sahin C, Lorenzen N, Lemminger L, Christiansen G, Møller IM, Vesterager LB, Pedersen L, Fog K, Kallunki P, Otzen DE. Antibodies against the C-terminus of α-synuclein modulate its fibrillation. Biophys Chem. 2017;220:34–41.View ArticlePubMedGoogle Scholar
- Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci. 2014;34:9441–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Hoyer W, Antony T, Cherny D, Heim G, Jovin T, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol. 2002;322:383–93.View ArticlePubMedGoogle Scholar
- Ruggeri FS, Vieweg S, Cendrowska U, Longo G, Chiki A, Lashuel HA, Dietler G. Nanoscale studies link amyloid maturity with polyglutamine diseases onset. Sci Rep. 2016;6:31155.View ArticlePubMedPubMed CentralGoogle Scholar
- Thirunavukkuarasu S, Jares-Erijman E, Jovin T. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein. J Mol Biol. 2008;378:1064–73.View ArticlePubMedGoogle Scholar
- Orte A, Clarke R, Balasubramanian S, Klenerman D. Determination of the fraction and stoichiometry of femtomolar levels of biomolecular complexes in an excess of monomer using single-molecule, two-color coincidence detection. Anal Chem. 2006;78:7707–15.View ArticlePubMedGoogle Scholar
- Ying L, Wallace M, Balasubramanian S, Klenerman D. Ratiometric analysis of single-molecule fluorescence resonance energy transfer using logical combinations of threshold criteria: A study of 12-mer DNA. J Phys Chem B. 2000;104:5171–8.View ArticleGoogle Scholar